Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3ml
Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement, Medicom has acquired the ownership of the product dossier, which is already registered in the UK and 5 EU countries with plans to commercialize the asset globally.
Medicom and Famar have also entered into a long term Manufacturing and Supply Agreement (MSA), with Famar being the exclusive manufacturer of this product for Medicom for a minimum period of 5 years, under specific terms and conditions. Both organizations expect the first commercial launch of the product, branded Zimed, in 4th quarter of 2021.
This agreement marks the sale for Farmer of its second own pharmaceutical dossier signifying a new era of continuous development and investments, under a new shareholders scheme.
“Medicom Healthcare is the largest volume supplier of ophthalmic dry eye drops to the NHS1 in the UK. We have embarked on an ambitious global expansion plan to sign up new distributors of our novel Evolve range of therapies specifically designed to protect the cornea from damage by unnecessary excipients that are a legacy of older technologies,” Simon Martin, CEO and Chairman of Medicom, said in a company news release. “The glaucoma market globally is predicted to exceed $3.8bn by 2026.2 Zimed will form another key pillar in our corneal protective growth strategy and we are delighted to have this agreement with a trusted, high quality manufacturer.”
Ian Cooper, CEO of Famar stated, “It is in the core of Famar’s strategy to further develop and expand its business and customers’ portfolio providing best quality services and products, repositioning Famar as the leader in the CDMO market globally. We take pride in our cutting edge scientific know how and our top expert employees. Our methodology and innovation characterizes the trusted and long lasting relationships with our customers throughout the world. We are pleased to welcome our new partner Medicom and look forward to cooperate in new projects.”
1: GPRx data, October 2020
2: Globaldata PharmaPoint: Glaucoma – Global Drug Forecast and Market Analysis to 2026